The inhibitory effect of octreotide on exocrine pancreatic secretion in conscious dogs.
The effects of somatostatin and its analogue, octreotide (SMS201-995), on pancreatic secretion and gastroduodenal motility in response to secretin and cholecystokinin octapeptide (CCK-8) were studied in five conscious dogs. Intravenous infusions of octreotide or somatostatin (1 nmol kg-1 h-1) inhibited periodic pancreatic secretion and the potentiation of fluid and bicarbonate responses to secretin at 60 ng kg-1 h-1 associated with the interdigestive gastroduodenal motility peaks (migrating motor complex). Pancreatic fluid and bicarbonate responses to secretin (125-1,000 ng kg-1 h-1) were not inhibited by octreotide or somatostatin. Pancreatic protein and enzyme responses to secretin and CCK-8 at 50 and 100, but not at 200 and 400, ng kg-1 h-1 were inhibited by octreotide and somatostatin. These inhibitory effects were similar to those of atropine (25 micrograms kg-1 h-1). The inhibition of protein responses to CCK-8 (100 ng kg-1 h-1) was dependent on octreotide dose. It is concluded that both octreotide and somatostatin, like atropine, inhibit interdigestive pancreatic secretion and the responses to small, but not large, doses of secretin and CCK-8 in conscious dogs.
Suzuki
T
T
National Institute for Physiological Sciences, Okazaki, Japan.
Naruse
S
S
Yanaihara
N
N
D000818:Animals; D004063:Digestion / Q000502:physiology; D004285:Dogs; D015282:Octreotide / Q000494:pharmacology*; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D012633:Secretin / Q000037:antagonists & inhibitors; D012844:Sincalide / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000494:pharmacology*; D013997:Time Factors
D012633:Secretin; D013004:Somatostatin; D012844:Sincalide; D015282:Octreotide